MedicGo
Global Vaccine Action Plan Lessons Learned II: Stakeholder Perspectives.
Metadata
Journalvaccine3.143Date
2020 Jun 04
4 months ago
Type
Journal Article
Volume
2020-Jul-14 / 38 : 5372-5378
Author
Hwang A 1, Veira C 2, Malvolti S 3, Cherian T 4, MacDonald N 5, Steffen C 6, Jones I 7, Hinman A 8, Mantel C 9
Affiliation
  • 2. Task Force for Global Health, 330 West Ponce de Leon Ave., Decatur, GA, 30030, USA. Electronic address: [email protected]
  • 3. MMGH Consulting GmbH, Kuerbergstrasse 1, 8049 Zurich, Switzerland. Electronic address: [email protected]
  • 4. MMGH Consulting GmbH, Kuerbergstrasse 1, 8049 Zurich, Switzerland. Electronic address: [email protected]
  • 5. Dalhousie University, IWK Health Centre, Halifax, Canada. Electronic address: [email protected]
  • 6. Immunization, Vaccines and Biological Department, World Health Organization, Geneva, Switzerland. Electronic address: [email protected]
  • 7. Jinja Publishing Ltd, Bishop's Stortford, United Kingdom. Electronic address: [email protected]
  • 8. Task Force for Global Health, 330 West Ponce de Leon Ave., Decatur, GA, 30030, USA. Electronic address: [email protected]
  • 9. MMGH Consulting GmbH, Kuerbergstrasse 1, 8049 Zurich, Switzerland. Electronic address: [email protected]
Doi
PMIDMESH
Abstract
INTRODUCTION: The Global Vaccine Action Plan (GVAP), unanimously endorsed by the World Health Assembly in 2012, defined an ambitious strategy to improve immunization. At the end of the decade, significant progress has been made but four of the five GVAP goals are likely to be missed. This report describes a set of surveys and interviews relating to GVAP, conducted to inform the immunization strategy for the next decade.
METHODS: Three surveys and two sets of semi-structured interviews were conducted from 2017 to 2019. Respondents consisted of immunization stakeholders at global, regional, and country levels, and included individuals who had been involved in the development and implementation of GVAP or its monitoring, evaluation and accountability (M&E/A) process; national immunization managers; academics; and personnel from non-governmental organizations and civil society organizations.
RESULTS: The surveys and interviews gave consistent results. They highlighted the value of GVAP in increasing visibility for immunization and the benefits of the GVAP M&E/A framework. The main limitations of GVAP were identified as the limited ownership by countries and other stakeholders leading to incomplete implementation of the strategy and poor accountability for achieving GVAP targets.
DISCUSSION: These results informed the review of GVAP and the development of its successor strategy, the Immunization Agenda 2030. In addition, these surveys and interviews identified two challenges in assessing the value of GVAP: the need to rely exclusively on stakeholder perspectives and difficulties in attributing benefits. These challenges are inherent in evaluating an over-arching strategy such as GVAP and should be factored into interpretation of the results.
Keywords: Evaluation GVAP Global Vaccine Action Plan IA2030 Immunization Agenda 2030 Immunization strategy
Fav
Like
Download
Share
Export
Cite
3.1
Vaccinevaccine
Metadata
LocationNetherlands
FromELSEVIER SCI LTD

No Data

© 2017 - 2020 Medicgo
Powered by some medical students